R&D Clinical Trials Round-Up: July/August 2026 While the volume of announcements hit a mid-year slump, July and August still produced an exciting array of updates across the drug development arena.
News FDA to decide on Takeda's psoriasis blockbuster hope in Q1 The FDA has started a review of the marketing application for Takeda's TYK2 inhibitor zasocitinib in psoriasis, setting up a decision in mid-March.
News Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest New data with Takeda's TYK2 inhibitor zasocitinib suggest it is significantly more effective than BMS's Sotyktu in the treatment of psoriasis.
News Lilly wins new FDA approval for eczema drug Ebglyss Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.
News Sanofi's bispecific lunsekimig has mixed readouts in phase 2 Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.
News J&J gets FDA okay for psoriasis drug icotrokinra Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.